Quantcast

Latest Generic drug Stories

2014-10-16 08:32:08

New Framework Provides More Predictable, Stable Environment for Payers and Manufacturers TORONTO, Oct. 16, 2014 /CNW/ - Canadians will save an estimated $3.8-billion through an unprecedented three-year agreement reached between Canada's provinces and territories and the generic pharmaceutical industry, Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), said today. "This national framework provides enormous additional savings to Canada's health-care...

2014-10-16 08:31:22

DUBLIN, Oct. 16, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR(®), which is a central nervous system stimulant indicated for the treatment of Attention Deficit...

2014-10-14 16:28:25

Robert W. Pollock Named President MOUNTAIN VIEW, Calif., Oct. 14, 2014 /PRNewswire/ -- Melbourne Laboratories(TM) announced today the appointment of Robert W. Pollock as the Company's founding President and Chief Scientific Officer. Pollock joins Melbourne from Lachman Consulting Services, where he had a distinguished 20-year career working with industry to address a myriad of regulatory, compliance and development issues. Prior to Lachman Pollock was with the United States Public...

2014-10-14 12:29:18

BOCA RATON, Fla., Oct. 14, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces the immediate launch of Mefenamic Acid 250mg Capsules. The U.S. Food and Drug Administration previously granted final approval for the Abbreviated New Drug Application (ANDA) for this product. This product is one of five approved Breckenridge ANDA products secured from the September 2013 acquisition of certain Cypress Pharmaceutical, Inc. product assets. Breckenridge's Mefenamic Acid...

2014-10-14 08:33:35

Providing longer market monopolies has not increased domestic R&D spending TORONTO, Oct. 14, 2014 /CNW/ - Research and development spending by brand-name drug companies in Canada has dropped to the lowest level ever recorded according to a recently released study by the federal government's Patented Medicine Price Review Board (PMPRB). The PMPRB's latest annual reports shows that in 2013 member companies of Canada's Research-Based Pharmaceutical Companies (Rx&D) spent only...

2014-10-01 23:11:28

Generic drug inflation has caused financial issues for drug stores and led insurers to create two generic drug tiers, which some researchers say is limiting access to needed drugs, according to Atlantic Information Services’s Drug Benefit News. Washington, DC (PRWEB) October 01, 2014 Generic drug prices are on the rise, with half of all retail generics increasing in price in the last 12 months. For its Sept. 26 issue, Atlantic Information Services, Inc.’s (AIS) Drug Benefit News (DBN)...

2014-10-01 08:31:32

BUENA, N.J., Oct. 1, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired two previously marketed ophthalmic drug products, in addition to the right to acquire three additional previously marketed injectable drug products from affiliates of Valeant Pharmaceuticals International, Inc. after the completion of the due diligence process. All of these products have been approved by the FDA...

2014-09-30 23:23:50

For generic drugmakers, Oct. 1 is crunch time, the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments (GDUFA) of 2012. Joan Janulis, a Hatch-Waxman pro and all-around expert on FDA regulation in the generic drug industry, will help attendees read between the lines of the GDUFA performance metrics, associated guidance documents and MAPPs, and provide a roadmap to the post-GDUFA paradigm....

2014-09-30 08:32:14

DUBLIN, Sept. 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release third quarter 2014 financial results on Wednesday, November 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, November 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the...

2014-09-25 16:26:46

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans(®), which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.